# Natco Pharma (NSE: NATCOPHARM) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/NATCOPHARM · Pivot · prices to 22 Oct 2026

Natco Pharma (NSE: NATCOPHARM) closed at ₹785.00 on 22 Oct 2026, up 0.13% on the day. With a market capitalisation of ₹14,063 Cr, it ranks 452nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 9.9× trailing earnings, against a return on equity of 15.4% in FY26. Over the past year the share price has fallen 3.3%. Its 52-week range is ₹773.60 (22 Oct 2026) to ₹1,226.80 (12 May 2026); the last close is 36.0% below the high. Promoters held 49.42% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹785.00 |
| Market cap | ₹14,063 Cr |
| P/E (trailing) | 9.9 |
| ROE | 15.4% (FY26) |
| ROCE | 16.3% (FY26) |
| Debt to equity | 0.08 |
| 52-week high | ₹1,226.80 (12 May 2026) |
| 52-week low | ₹773.60 (22 Oct 2026) |
| 1-year return | −3.3% |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹4,430 Cr | ₹1,883 Cr |
| FY24 | ₹3,999 Cr | ₹1,388 Cr |
| FY23 | ₹2,707 Cr | ₹715 Cr |
| FY22 | ₹1,945 Cr | ₹170 Cr |
| FY21 | ₹2,052 Cr | ₹442 Cr |
| FY20 | ₹1,915 Cr | ₹458 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 49.42%
- Foreign institutions: 16.99%
- Domestic institutions: 5.62%
- Non-institutions: 27.97%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Jubilant Pharmova](https://app.pivotnow.in/stock/JUBLPHARMA) | ₹930.80 | ₹14,848 Cr | 37.1 | 13.4% |
| [Poly Medicure](https://app.pivotnow.in/stock/POLYMED) | ₹1,479.10 | ₹14,686 Cr | 46.7 | 10.4% |
| [Vijaya Diagnostic Centre](https://app.pivotnow.in/stock/VIJAYA) | ₹1,382.60 | ₹14,324 Cr | 82.5 | 18.1% |
| [Indegene](https://app.pivotnow.in/stock/INDGN) | ₹577.95 | ₹14,171 Cr | 34.8 | 12.8% |
| [Marksans Pharma](https://app.pivotnow.in/stock/MARKSANS) | ₹295.80 | ₹13,343 Cr | 32.1 | 13.8% |
| [Concord Biotech](https://app.pivotnow.in/stock/CONCORDBIO) | ₹1,298.00 | ₹13,294 Cr | 52.4 | — |

## Questions and answers

### What is the share price of Natco Pharma today?

Natco Pharma (NSE: NATCOPHARM) last closed at ₹785.00 on 22 Oct 2026. Its 52-week high is ₹1,226.80 and its 52-week low is ₹773.60.

### What is the market cap of Natco Pharma?

Natco Pharma's market capitalisation is ₹14,063 Cr (₹14,063 Cr) at the 22 Oct 2026 close, ranking 452nd among the NSE companies Pivot tracks.

### What is the P/E ratio of Natco Pharma?

Natco Pharma trades at a trailing P/E of 9.9. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 46.7.

### What is the ROE and ROCE of Natco Pharma?

Return on equity was 15.4% in FY26 and return on capital employed was 16.3% in FY26 (consolidated figures).

### Is Natco Pharma a debt-free company?

No. Natco Pharma's debt-to-equity ratio was 0.08 in FY26, with total debt of ₹100 Cr.

### How has Natco Pharma stock performed over the last year?

Natco Pharma's share price has fallen 3.3% over the past year, −15.7% over three months and −2.7% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Natco Pharma?

As of 30 Jun 2026: promoters 49.42%, foreign institutions 16.99%, domestic institutions 5.62%, non-institutions 27.97%.

### Who are Natco Pharma's competitors?

The listed Pharma & Healthcare companies closest to Natco Pharma by market cap are Jubilant Pharmova, Poly Medicure, Vijaya Diagnostic Centre, Indegene, Marksans Pharma and Concord Biotech.

### Is Natco Pharma a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Natco Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on NATCOPHARM against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.